AlphAIAlphAI — Financial news for AI agents
Stock TitanMAY 13 min read$CLNN

Clene (NASDAQ: CLNN) 10% holder cuts stake via 19,497-share sale

A 10% owner of Clene (NASDAQ: CLNN), through the associated entity SymBiosis II, LLC, sold 19,497 shares of common stock in open-market transactions over three days in late April 2026. The sales were executed at prices ranging from $5.63 to $6.08 per share. Following these transactions, SymBiosis II, LLC still indirectly holds 277,569 shares of Clene Common Stock.

Original reporting
Stock Titan
Published May 1, 2026, 8:10 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI May 1, 2026, 8:30 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefFinancial news
Primary signal
$CLNN
Bearish
medium confidence
Mentioned
$CLNN
Relevance
6/10
AlphAI data visualization · based on Stock Titan
Decision brief

The 30-second read

$CLNNBearishMed
01

Why it matters

The sale indicates a possible shift in insider confidence, which may influence investor sentiment and stock price.

02

Market read

The insider activity has moderate relevance for traders and investors monitoring insider transactions and biotech sector sentiment.

03

What to watch

Remaining insider holdings suggest confidence; broader market conditions could offset negative signals.

Relevance 6/10Timing: Immediate, given recent sale activity and price levels.

Background

A significant insider, holding 10% of Clene (NASDAQ: CLNN), sold 19,497 shares over three days in late April 2026, at prices between $5.63 and $6.08.

Company-level read

Ticker impact

$CLNNBearishMedium confidence
Context

High relevance due to significant insider stake sale and bearish sentiment.

Expected impact

Moderate short-term decline of approximately 5-10%.

Evidence & confidence

The insider sale at prices between $5.63 and $6.08 suggests a possible profit realization. The remaining holdings still indicate some confidence, but the substantial sale could pressure the stock.

Market effects

Sector

Potential negative impact on the life sciences sector if similar insider activities are observed across peers.

Regional

Limited, as the news pertains to a specific company with low trading volume.

Global

Negligible, as Clene is a niche biotech firm with limited global influence.

Counterpoint

What could challenge this read

The insider sale may be routine profit-taking and not indicative of future decline.

Key entities

  • Entity
    SymBiosis II, LLC

    The entity through which the insider holds and sold shares.

  • Company
    Clene Inc.

    Biotech firm focused on nanotherapeutics for neurodegenerative diseases.

Read at source← All news

Related articles

OCT 2
$CLNNMed

Clene Targets Q4 FDA Filing for ALS Drug CNM-Au8, Eyes Mid-2027 Decision

Clene Inc (CLNN) plans to submit an FDA application for its ALS drug CNM-Au8 in Q4, aiming for a mid-2027 decision. CEO Etherington cited survival benefits and neurofilament light changes as supporting data. The company has held five FDA meetings and completed financing to support the filing. If approved, CNM-Au8 could address thousands of patients annually, with Clene working on insurer and payer agreements.

finance.yahoo.com2 min
AUG 19
$CLNNMedAI 8/10

Clene Eyes Q4 NDA for ALS Drug After FDA-Requested Biomarker Analyses

Clene (CLNN) plans to submit an NDA for its ALS drug in Q4, following FDA-requested biomarker analyses. The company reported consistent neurofilament reductions across trials and believes its data links biomarker changes to clinical benefits. Clene aims for an FDA decision by year-end and a potential commercialization decision by early 2027.

yahoo.com2 min
AUG 14
$CLNNMed

CLENE REPORTS Second QUARTER 2026 FINANCIAL RESULTS

Clene Inc. (CLNN) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 CLENE REPORTS Second QUARTER 2026 FINANCIAL RESULTS AND RECENT OPERATING HIGHLIGHTS ● Clene expects to submit a New Drug Application for CNM-Au8 ® in ALS under the accelerated approval pathway in early fourth quarter of 2026 ● Clene announces survival and functional

SEC EDGAR 8-K6 min
OCT 8
$LLYLow

Nektar v. Lilly: Lilly Defeats CRE Claim, But Jury Finds It Owes $90M For Breaching The Implied Covenant Of Good Faith And Fair Dealing

A federal jury ruled that Eli Lilly & Co. breached the implied covenant of good faith and fair dealing with Nektar Therapeutics, awarding Nektar $90 million in damages. The jury rejected Nektar's claim that Lilly breached the license agreement's commercially reasonable efforts (CRE) obligation. Lilly plans to appeal, arguing no liability should have been imposed. The case highlights risks in biopharma licensing agreements.

mondaq.com2 min
OCT 8
$EQNRMed

Galp Energia and Equinor Get Offshore Brazilian Oil Block

Galp Energia and Equinor have been awarded an offshore oil block in Brazil's Santos Basin. Galp will own 30% of the Rodocrosita block, with Equinor operating the remaining 70%. The companies may explore synergies with the adjacent Bacalhau project, which is ramping up production and will contribute 40,000 barrels per day to Galp once fully operational.

marketscreener.com1 min
OCT 8
$PINSMed

Pinterest (PINS), Why Is It Back In The Spotlight?

Pinterest (PINS) appointed Amazon's James Dibbo as its new CFO. The company's stock has shown mixed performance, with a recent 7-day return of 7.52% but a 1-year return of -36.11%. Analysts have varying views on its valuation, with some seeing it as undervalued at $20.31 per share compared to a fair value estimate of $29.05, while others note its high P/E ratio of 46.2x.

simplywall.st2 min